Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8-week randomized double-blind trial of LCZ696 vs olmesartan in Japanese patients with essential hypertension
jRCT2080221840Phase 3
- Sponsor
- Novartis
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sacubitril + valsartan in essential hypertension (3 arms), sponsored by Novartis.
02
Drugs
sacubitril + valsartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2080221840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221840.